LAZCLUZE (LAZERTINIB 80 MG )
Price
FAQ's
Details
Patients Stories
Important Guide
Lazcluze (Lazertinib)
- Drug class: Third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI)
- Indication: Used for certain patients with EGFR-mutated non-small cell lung cancer (NSCLC).
- Mechanism of action: Blocks abnormal EGFR signals that help cancer cells grow and spread.
- Administration: Oral tablet, usually taken once daily as prescribed.
- Common side effects:
- Rash
- Dry skin
- Diarrhea
- Nail changes
- Fatigue
- Decreased appetite
- Serious side effects:
- Lung inflammation (interstitial lung disease/pneumonitis)
- Heart-related effects
- Liver function abnormalities
- Monitoring: Regular assessment of liver function, heart status, and treatment response may be required.
If you need details on dose, indications, adverse effects, or comparison with Osimertinib (Tagrisso), let me know.

